{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:23:22Z","timestamp":1771871002567,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T00:00:00Z","timestamp":1425081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40261-015-0278-6","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T12:07:04Z","timestamp":1425038824000},"page":"267-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02)"],"prefix":"10.1007","volume":"35","author":[{"given":"Bimal K.","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Matschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candace","family":"Bramson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Salageanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,28]]},"reference":[{"key":"278_CR1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2013.272","volume":"309","author":"CM Jones","year":"2013","unstructured":"Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309:657\u20139.","journal-title":"JAMA."},{"key":"278_CR2","first-page":"e59","volume":"3","author":"AG White","year":"2011","unstructured":"White AG. Economic impact of opioid abuse, dependence, and misuse. Am J Pharm Benefits. 2011;3:e59\u201370.","journal-title":"Am J Pharm Benefits."},{"key":"278_CR3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/03639045.2012.680468","volume":"39","author":"DJ Mastropietro","year":"2013","unstructured":"Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm. 2013;39:611\u201324.","journal-title":"Drug Dev Ind Pharm."},{"key":"278_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.36076\/ppj.2011\/14\/391","volume":"14","author":"F Johnson","year":"2011","unstructured":"Johnson F, Setnik B. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability. Pain Physician. 2011;14:391\u2013406.","journal-title":"Pain Physician."},{"key":"278_CR5","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1155\/2013\/952082","volume":"18","author":"B Setnik","year":"2013","unstructured":"Setnik B, Goli V, Levy-Cooperman N, Mills C, Shram M, Smith I. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. Pain Res Manag. 2013;18:e55\u201362.","journal-title":"Pain Res Manag."},{"key":"278_CR6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/pme.12148","volume":"14","author":"B Setnik","year":"2013","unstructured":"Setnik B, Sommerville K, Goli V, Han L, Webster L. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users. Pain Med. 2013;14:1173\u201386.","journal-title":"Pain Med."},{"key":"278_CR7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/11530800-000000000-00000","volume":"29","author":"J Stauffer","year":"2009","unstructured":"Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009;29:777\u201390.","journal-title":"Clin Drug Investig."},{"key":"278_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11593390-000000000-00000","volume":"11","author":"LR Webster","year":"2011","unstructured":"Webster LR, Johnson FK, Stauffer J, Setnik B, Ciric S. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D. 2011;11:259\u201375.","journal-title":"Drugs R D."},{"key":"278_CR9","first-page":"593","volume":"10","author":"KW Sommerville","year":"2013","unstructured":"Sommerville KW. Development of a oxycodone\/naltrexone combination capsule (ALO-02). Neurotherapeutics. 2013;10:593\u2013600.","journal-title":"Neurotherapeutics."},{"key":"278_CR10","unstructured":"Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Drug Abuse Warning Network, 2011: National estimates of drug-related emergency department visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville: US Department of Health and Human Services; 2013."},{"key":"278_CR11","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: volume I. Summary of national findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 findings). Rockville: US Department of Health and Human Services; 2010."},{"key":"278_CR12","first-page":"40","volume":"23","author":"R Weathermon","year":"1999","unstructured":"Weathermon R, Crabb DW. Alcohol and medication interactions. Alcohol Res Health. 1999;23:40\u201354.","journal-title":"Alcohol Res Health."},{"key":"278_CR13","volume-title":"Awareness topic: mitigating the risks of ethanol induced dose dumping from oral sustained\/controlled release dosage forms","author":"RJ Meyer","year":"2005","unstructured":"Meyer RJ, Hussain AS. Awareness topic: mitigating the risks of ethanol induced dose dumping from oral sustained\/controlled release dosage forms. Washington DC: US Food and Drug Administration; 2005."},{"key":"278_CR14","first-page":"17","volume":"182","author":"Council for International Organizations of Medical Sciences","year":"2002","unstructured":"Council for International Organizations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects. Bull Med Ethics. 2002;182:17\u201323.","journal-title":"Bull Med Ethics"},{"key":"278_CR15","unstructured":"International Conference on Harmonization. E6 Good Clinical Practice. 1996. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf . Accessed 22 Aug 2013."},{"key":"278_CR16","unstructured":"World Medical Association. Declaration of Helsinki. 2008. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/ . Accessed 22 Aug 2013."},{"key":"278_CR17","volume-title":"Food-effect bioavailability and fed bioequivalence studies","author":"Center for Drug Evaluation and Research","year":"2002","unstructured":"Center for Drug Evaluation and Research. Food-effect bioavailability and fed bioequivalence studies. Rockville: US Food and Drug Administration; 2002."},{"key":"278_CR18","unstructured":"US Food and Drug Administration. Information for healthcare professionals: hydromorphone hydrochloride extended-release capsules (marketed as Palladone). In: FDA Alert [7\/2005]: Postmarket Drug Safety Information for Patients and Providers. 2005. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm129288.htm . Accessed 19 Aug 2013."},{"key":"278_CR19","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0140-6736(84)91663-5","volume":"2","author":"L Hendeles","year":"1984","unstructured":"Hendeles L, Wubbena P, Weinberger M. Food-induced dose dumping of once-a-day theophylline. Lancet. 1984;2:1471.","journal-title":"Lancet."},{"key":"278_CR20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1208\/s12248-008-9046-3","volume":"10","author":"DA Volpe","year":"2008","unstructured":"Volpe DA, Asafu-Adjaye EB, Ellison CD, Doddapaneni S, Uppoor RS, Khan MA. Effect of ethanol on opioid drug permeability through caco-2 cell monolayers. AAPS J. 2008;10:360\u20132.","journal-title":"AAPS J."},{"key":"278_CR21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/j.1552-4604.1982.tb02649.x","volume":"22","author":"RJ Wills","year":"1982","unstructured":"Wills RJ, Crouthamel WG, Iber FL, Perkal MB. Influence of alcohol on the pharmacokinetics of diazepam controlled-release formulation in healthy volunteers. J Clin Pharmacol. 1982;22:557\u201361.","journal-title":"J Clin Pharmacol."},{"key":"278_CR22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/0091270011403740","volume":"52","author":"FK Johnson","year":"2012","unstructured":"Johnson FK, Ciric S, Boudriau S, Kisicki J, Stauffer J. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol. 2012;52:747\u201356.","journal-title":"J Clin Pharmacol."},{"key":"278_CR23","first-page":"186","volume":"6","author":"B Malhotra","year":"2014","unstructured":"Malhotra B, Matschke K, Bramson C, Wang Q, Salageanu J. Relative bioavailability study of an abuse-deterrent formulation of extended-release oxycodone with sequestered naltrexone (ALO-02) versus immediate-release oxycodone tablets in healthy volunteers. J Bioequiv Availab. 2014;6:186\u201391.","journal-title":"J Bioequiv Availab."},{"key":"278_CR24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","volume":"79","author":"B Lalovic","year":"2006","unstructured":"Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79:461\u201379.","journal-title":"Clin Pharmacol Ther."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0278-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0278-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0278-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:09:16Z","timestamp":1651363756000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0278-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,28]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0278-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,28]]}}}